Use of the Chinchilla Model to Evaluate the Vaccinogenic Potential of the Moraxella catarrhalis Filamentous Hemagglutinin-like Proteins MhaB1 and MhaB2

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Shaffer, Teresa L ^a   Balder, Rachel ^a   Buskirk, Sean W ^a   Hogan, Robert J ^a   Lafontaine, Eric R ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; MHAB1 VACCINE; MHAB2 VACCINE; POLYPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; CHINCHILLA; CONTROLLED STUDY; DRUG SCREENING; HUMAN; HUMAN CELL; MORAXELLA CATARRHALIS; MORAXELLACEAE INFECTION; NASOPHARYNX; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; VACCINATION;

ADHESINS, BACTERIAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL ADHESION; BACTERIAL PROTEINS; BACTERIAL VACCINES; BLOTTING, WESTERN; CELL LINE, TUMOR; CHINCHILLA; DISEASE MODELS, ANIMAL; HAEMOPHILUS INFLUENZAE; HEMAGGLUTININS; HOST-PATHOGEN INTERACTIONS; HUMANS; MORAXELLA (BRANHAMELLA) CATARRHALIS; MORAXELLACEAE INFECTIONS; MUTATION; NASOPHARYNX; OTITIS MEDIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANIMALIA; CHINCHILLIDAE; HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; STREPTOCOCCUS PNEUMONIAE;

EID: 84879750486     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067881     Document Type: Article

References (133)

1. Cripps AW, Otczyk DC, Kyd JM, (2005) Bacterial otitis media: a vaccine preventable disease? Vaccine 23: 2304-2310.
2. Giebink GS, Kurono Y, Bakaletz LO, Kyd JM, Barenkamp SJ, et al. (2005) Recent advances in otitis media. 6. Vaccine. Ann Otol Rhinol Laryngol Suppl 194: 86-103.
3. Karalus R, Campagnari A, (2000) Moraxella catarrhalis: a review of an important human mucosal pathogen. Microbes Infect 2: 547-559.
4. Murphy TF, (2005) Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges. Expert Rev Vaccines 4: 843-853.
5. Pichichero ME, Casey JR, (2002) Otitis media. Expert Opin Pharmacother 3: 1073-1090.
6. Verduin CM, Hol C, Fleer A, van Dijk H, van Belkum A, (2002) Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev 15: 125-144.
7. Faden H, (2001) The microbiologic and immunologic basis for recurrent otitis media in children. Eur J Pediatr 160: 407-413.
8. Enright MC, McKenzie H, (1997) Moraxella (Branhamella) catarrhalis-clinical and molecular aspects of a rediscovered pathogen. J Med Microbiol 46: 360-371.
9. Arguedas A, Kvaerner K, Liese J, Schilder AG, Pelton SI, (2010) Otitis media across nine countries: disease burden and management. Int J Pediatr Otorhinolaryngol 74: 1419-1424.
10. Diagnosis and management of acute otitis media. Pediatrics 113: 1451-1465.
11. Del Beccaro MA, Mendelman PM, Inglis AF, Richardson MA, Duncan NO, et al. (1992) Bacteriology of acute otitis media: a new perspective. J Pediatr 120: 81-84.
12. Faden H, Duffy L, Wasielewski R, Wolf J, Krystofik D, et al. (1997) Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/Williamsville Pediatrics. J Infect Dis 175: 1440-1445.
13. Faden H, Stanievich J, Brodsky L, Bernstein J, Ogra PL, (1990) Changes in nasopharyngeal flora during otitis media of childhood. Pediatr Infect Dis J 9: 623-626.
14. Ruuskanen O, Heikkinen T (1994) Otitis media: etiology and diagnosis. Pediatr Infect Dis J 13: S23-S26; discussion S50-S54.
15. Stool SE, Field MJ, (1989) The impact of otitis media. Pediatr Infect Dis J 8: S11-S14.
16. Klein JO, (1994) Otitis media. Clin Infect Dis 19: 823-833.
17. Klein JO, (2000) The burden of otitis media. Vaccine 19Suppl 1: S2-8.
18. Klein JO, Teele DW, Pelton SI, (1992) New concepts in otitis media: results of investigations of the Greater Boston Otitis Media Study Group. Adv Pediatr 39: 127-156.
19. Murphy TF, (1996) Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Microbiol Rev 60: 267-279.
20. Acuin J (2004) Chronic suppurative otitis media: burden of illness and management options. World Health Organization website. Available: http://www.who.int/pbd/deafness/activities/hearing_care/otitis_media.pdf). Accessed 2013 June 4.
21. Berman S, (1995) Otitis media in developing countries. Pediatrics 96: 126-131.
22. Murphy TF, Brauer AL, Grant BJ, Sethi S, (2005) Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med 172: 195-199.
23. Sethi S, Evans N, Grant BJ, Murphy TF, (2002) New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 347: 465-471.
24. Sethi S, Murphy TF, (2001) Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review. Clin Microbiol Rev 14: 336-363.
25. NIH-NHLBI website. Morbidity and Mortality: 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases. Available: http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf. Accessed 2013 June 4.
26. Strassels SA, Smith DH, Sullivan SD, Mahajan PS, (2001) The costs of treating COPD in the United States. Chest 119: 344-352.
27. Sullivan SD, Ramsey SD, Lee TA, (2000) The economic burden of COPD. Chest 117: 5S-9S.
28. Hunter MH, King DE, (2001) COPD: management of acute exacerbations and chronic stable disease. Am Fam Physician 64: 603-612.
29. Hurd S, (2000) The impact of COPD on lung health worldwide: epidemiology and incidence. Chest 117: 1S-4S.
30. World Health Organization website. World Health Statistics 2008. Available: http://www.who.int/gho/publications/world_health_statistics/EN_WHS08_Full.pdf. Accessed 2013 June 4.
31. World Health Organization website. Fact Sheet: The Top Ten Causes of Death (2008). Available: http://www.who.int/mediacentre/factsheets/fs310_2008.pdf.Accessed 2013 June 4.
32. Ahmed A, Broides A, Givon-Lavi N, Peled N, Dagan R, et al. (2008) Clinical and laboratory aspects of Moraxella catarrhalis bacteremia in children. Pediatr Infect Dis J 27: 459-461.
33. Berner R, Schumacher RF, Brandis M, Forster J, (1996) Colonization and infection with Moraxella catarrhalis in childhood. Eur J Clin Microbiol Infect Dis 15: 506-509.
34. Neumayer U, Schmidt HK, Mellwig KP, Kleikamp G, (1999) Moraxella catarrhalis endocarditis: report of a case and literature review. J Heart Valve Dis 8: 114-117.
35. Stefanou J, Agelopoulou AV, Sipsas NV, Smilakou N, Avlami A, (2000) Moraxella catarrhalis endocarditis: case report and review of the literature. Scand J Infect Dis 32: 217-218.
36. Thorsson B, Haraldsdottir V, Kristjansson M, (1998) Moraxella catarrhalis bacteraemia. A report on 3 cases and a review of the literature. Scand J Infect Dis 30: 105-109.
37. Turner HR, Taylor MR, Lockwood WR, (1985) Branhamella catarrhalis endocarditis in a patient receiving hemodialysis. South Med J 78: 1021-1022.
38. Utsunomiya T, Nakahara K, Kuramochi M, Hashiba K, Uzuka Y, et al. (1984) [Branhamella (Neisseria) catarrhalis endocarditis after insertion of a mitral prosthesis: a case report]. Nippon Naika Gakkai Zasshi 73: 1506-1511.
39. Catlin BW, (1990) Branhamella catarrhalis: an organism gaining respect as a pathogen. Clin Microbiol Rev 3: 293-320.
40. Christensen JJ (1999) Moraxella (Branhamella) catarrhalis: clinical, microbiological and immunological features in lower respiratory tract infections. APMIS Suppl 88: 1-36.
41. Nigrovic LE, Kuppermann N, Malley R, (2008) Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era. Acad Emerg Med 15: 522-528.
42. Brook I, (2005) The role of bacteria in chronic rhinosinusitis. Otolaryngol Clin North Am 38: 1171-1192.
43. Brook I, (2005) Microbiology and antimicrobial management of sinusitis. J Laryngol Otol 119: 251-258.
44. Brook I, Foote PA, Frazier EH, (2005) Microbiology of acute exacerbation of chronic sinusitis. Ann Otol Rhinol Laryngol 114: 573-576.
45. Bingen E, Cohen R, Jourenkova N, Gehanno P, (2005) Epidemiologic study of conjunctivitis-otitis syndrome. Pediatr Infect Dis J 24: 731-732.
46. Buznach N, Dagan R, Greenberg D, (2005) Clinical and bacterial characteristics of acute bacterial conjunctivitis in children in the antibiotic resistance era. Pediatr Infect Dis J 24: 823-828.
47. Jacobs MR, Bajaksouzian S, Windau A, Good CE, Lin G, et al. (2004) Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U S Surveillance Study. Clin Lab Med 24: 503-530.
48. Klugman KP (1996) The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxycillin and alternative agents, for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. J Antimicrob Chemother 38 Suppl A: 133-140.
49. Manninen R, Huovinen P, Nissinen A, (1997) Increasing antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in Finland. J Antimicrob Chemother 40: 387-392.
50. Richter SS, Winokur PL, Brueggemann AB, Huynh HK, Rhomberg PR, et al. (2000) Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998. Antimicrob Agents Chemother 44: 444-446.
51. Kadry AA, Fouda SI, Elkhizzi NA, Shibl AM, (2003) Correlation between susceptibility and BRO type enzyme of Moraxella catarrhalis strains. Int J Antimicrob Agents 22: 532-536.
52. Schmitz FJ, Beeck A, Perdikouli M, Boos M, Mayer S, et al. (2002) Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates. J Clin Microbiol 40: 1546-1548.
53. Johnson DM, Sader HS, Fritsche TR, Biedenbach DJ, Jones RN, (2003) Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 47: 373-376.
54. Esel D, Ay-Altintop Y, Yagmur G, Gokahmetoglu S, Sumerkan B, (2007) Evaluation of susceptibility patterns and BRO beta-lactamase types among clinical isolates of Moraxella catarrhalis. Clin Microbiol Infect 13: 1023-1025.
55. Bootsma HJ, Aerts PC, Posthuma G, Harmsen T, Verhoef J, et al. (1999) Moraxella (Branhamella) catarrhalis BRO beta-lactamase: a lipoprotein of gram-positive origin? J Bacteriol 181: 5090-5093.
56. Bootsma HJ, van Dijk H, Vauterin P, Verhoef J, Mooi FR, (2000) Genesis of BRO beta-lactamase-producing Moraxella catarrhalis: evidence for transformation-mediated horizontal transfer. Mol Microbiol 36: 93-104.
57. Garcia-Rodriguez JA, Fresnadillo Martinez MJ, (2002) Dynamics of nasopharyngeal colonization by potential respiratory pathogens. J Antimicrob Chemother 50Suppl S2: 59-73.
58. Faden H, Harabuchi Y, Hong JJ, (1994) Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media. J Infect Dis 169: 1312-1317.
59. Gerlach RG, Hensel M, (2007) Protein secretion systems and adhesins: the molecular armory of Gram-negative pathogens. Int J Med Microbiol 297: 401-415.
60. Beachey EH, (1981) Bacterial adherence: adhesin-receptor interactions mediating the attachment of bacteria to mucosal surface. J Infect Dis 143: 325-345.
61. Boyle EC, Finlay BB, (2003) Bacterial pathogenesis: exploiting cellular adherence. Curr Opin Cell Biol 15: 633-639.
62. Hauck CR, (2002) Cell adhesion receptors- signaling capacity and exploitation by bacterial pathogens. Med Microbiol Immunol 191: 55-62.
63. Jacob-Dubuisson F, Locht C, Antoine R, (2001) Two-partner secretion in Gram-negative bacteria: a thrifty, specific pathway for large virulence proteins. Mol Microbiol 40: 306-313.
64. Niemann HH, Schubert WD, Heinz DW, (2004) Adhesins and invasins of pathogenic bacteria: a structural view. Microbes Infect 6: 101-112.
65. St Geme JW 3rd (1997) Bacterial adhesins: determinants of microbial colonization and pathogenicity. Adv Pediatr 44: 43-72.
66. Lafontaine ER, Cope LD, Aebi C, Latimer JL, McCracken GH Jr, et al. (2000) The UspA1 protein and a second type of UspA2 protein mediate adherence of Moraxella catarrhalis to human epithelial cells in vitro. J Bacteriol 182: 1364-1373.
67. Balder R, Hassel J, Lipski S, Lafontaine ER, (2007) Moraxella catarrhalis strain O35E expresses two filamentous hemagglutinin-like proteins that mediate adherence to human epithelial cells. Infect Immun 75: 2765-2775.
68. Plamondon P, Luke NR, Campagnari AA, (2007) Identification of a novel two-partner secretion locus in Moraxella catarrhalis. Infect Immun 75: 2929-2936.
69. Balder R, Krunkosky TM, Nguyen CQ, Feezel L, Lafontaine ER, (2009) Hag mediates adherence of Moraxella catarrhalis to ciliated human airway cells. Infect Immun 77: 4597-4608.
70. Bullard B, Lipski SL, Lafontaine ER, (2005) Hag directly mediates the adherence of Moraxella catarrhalis to human middle ear cells. Infect Immun 73: 5127-5136.
71. Akimana C, Lafontaine ER, (2007) The Moraxella catarrhalis outer membrane protein CD contains two distinct domains specifying adherence to human lung cells. FEMS Microbiol Lett 271: 12-19.
72. Holm MM, Vanlerberg SL, Foley IM, Sledjeski DD, Lafontaine ER, (2004) The Moraxella catarrhalis porin-like outer membrane protein CD is an adhesin for human lung cells. Infect Immun 72: 1906-1913.
73. Lipski SL, Akimana C, Timpe JM, Wooten RM, Lafontaine ER, (2007) The Moraxella catarrhalis Autotransporter McaP Is a Conserved Surface Protein That Mediates Adherence to Human Epithelial Cells through Its N-Terminal Passenger Domain. Infect Immun 75: 314-324.
74. Timpe JM, Holm MM, Vanlerberg SL, Basrur V, Lafontaine ER, (2003) Identification of a Moraxella catarrhalis outer membrane protein exhibiting both adhesin and lipolytic activities. Infect Immun 71: 4341-4350.
75. Sambrook J, Russell DW (2001) Molecular Cloning: A Laboratory Manual (Third Edition): Cold Spring Harbor Laboratory Press.
76. Murphy TF, Loeb MR, (1989) Isolation of the outer membrane of Branhamella catarrhalis. Microb Pathog 6: 159-174.
77. Cope LD, Lafontaine ER, Slaughter CA, Hasemann CA Jr, Aebi C, et al. (1999) Characterization of the Moraxella catarrhalis uspA1 and uspA2 genes and their encoded products. J Bacteriol 181: 4026-4034.
78. Patrick CC, Kimura A, Jackson MA, Hermanstorfer L, Hood A, et al. (1987) Antigenic characterization of the oligosaccharide portion of the lipooligosaccharide of nontypable Haemophilus influenzae. Infect Immun 55: 2902-2911.
79. Song JM, Hossain J, Yoo DG, Lipatov AS, Davis CT, et al. (2010) Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405: 165-175.
80. Helminen ME, Maciver I, Latimer JL, Cope LD, McCracken GH Jr, et al. (1993) A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model. Infect Immun 61: 2003-2010.
81. Pearson MM, Lafontaine ER, Wagner NJ, St Geme JW 3rd, Hansen EJ (2002) A hag mutant of Moraxella catarrhalis strain O35E is deficient in hemagglutination, autoagglutination, and immunoglobulin D-binding activities. Infect Immun 70: 4523-4533.
82. Aebi C, Lafontaine ER, Cope LD, Latimer JL, Lumbley SL, et al. (1998) Phenotypic effect of isogenic uspA1 and uspA2 mutations on Moraxella catarrhalis 035E. Infect Immun 66: 3113-3119.
83. Murphy TF, Kirkham C, DeNardin E, Sethi S, (1999) Analysis of antigenic structure and human immune response to outer membrane protein CD of Moraxella catarrhalis. Infect Immun 67: 4578-4585.
84. Luke NR, Jurcisek JA, Bakaletz LO, Campagnari AA, (2007) Contribution of Moraxella catarrhalis type IV pili to nasopharyngeal colonization and biofilm formation. Infect Immun 75: 5559-5564.
85. Bakaletz LO, Murwin DM, Billy JM, (1995) Adenovirus serotype 1 does not act synergistically with Moraxella (Branhamella) catarrhalis to induce otitis media in the chinchilla. Infect Immun 63: 4188-4190.
86. Hoopman TC, Liu W, Joslin SN, Pybus C, Sedillo JL, et al. (2012) Use of the chinchilla model for nasopharyngeal colonization to study gene expression by Moraxella catarrhalis. Infect Immun 80: 982-995.
87. Murphy TF, Kirkham C, Liu DF, Sethi S, (2003) Human immune response to outer membrane protein CD of Moraxella catarrhalis in adults with chronic obstructive pulmonary disease. Infect Immun 71: 1288-1294.
88. LaFontaine ER, Snipes LE, Bullard B, Brauer AL, Sethi S, et al. (2009) Identification of domains of the Hag/MID surface protein recognized by systemic and mucosal antibodies in adults with chronic obstructive pulmonary disease following clearance of Moraxella catarrhalis. Clin Vaccine Immunol 16: 653-659.
89. Murphy TF, Brauer AL, Aebi C, Sethi S, (2005) Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease. Infect Immun 73: 8161-8166.
90. Murphy TF, Brauer AL, Aebi C, Sethi S, (2005) Identification of surface antigens of Moraxella catarrhalis as targets of human serum antibody responses in chronic obstructive pulmonary disease. Infect Immun 73: 3471-3478.
91. Stutzmann Meier P, Heiniger N, Troller R, Aebi C, (2003) Salivary antibodies directed against outer membrane proteins of Moraxella catarrhalis in healthy adults. Infect Immun 71: 6793-6798.
92. Meier PS, Freiburghaus S, Martin A, Heiniger N, Troller R, et al. (2003) Mucosal immune response to specific outer membrane proteins of Moraxella catarrhalis in young children. Pediatr Infect Dis J 22: 256-262.
93. Chen D, Barniak V, VanDerMeid KR, McMichael JC, (1999) The levels and bactericidal capacity of antibodies directed against the UspA1 and UspA2 outer membrane proteins of Moraxella (Branhamella) catarrhalis in adults and children. Infect Immun 67: 1310-1316.
94. Mathers K, Leinonen M, Goldblatt D, (1999) Antibody response to outer membrane proteins of Moraxella catarrhalis in children with otitis media. Pediatr Infect Dis J 18: 982-988.
95. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, et al. (2001) Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344: 403-409.
96. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, et al. (2006) Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367: 740-748.
97. Revai K, McCormick DP, Patel J, Grady JJ, Saeed K, et al. (2006) Effect of pneumococcal conjugate vaccine on nasopharyngeal bacterial colonization during acute otitis media. Pediatrics 117: 1823-1829.
98. Brook I, Gober AE, (2007) Frequency of recovery of pathogens from the nasopharynx of children with acute maxillary sinusitis before and after the introduction of vaccination with the 7-valent pneumococcal vaccine. Int J Pediatr Otorhinolaryngol 71: 575-579.
99. Brook I, Foote PA, Hausfeld JN, (2006) Frequency of recovery of pathogens causing acute maxillary sinusitis in adults before and after introduction of vaccination of children with the 7-valent pneumococcal vaccine. J Med Microbiol 55: 943-946.
100. Becker PD, Bertot GM, Souss D, Ebensen T, Guzman CA, et al. (2007) Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model. Infect Immun 75: 1778-1784.
101. Liu DF, McMichael JC, Baker SM, (2007) Moraxella catarrhalis outer membrane protein CD elicits antibodies that inhibit CD binding to human mucin and enhance pulmonary clearance of M. catarrhalis in a mouse model. Infect Immun 75: 2818-2825.
102. Peng D, Choudhury BP, Petralia RS, Carlson RW, Gu XX, (2005) Roles of 3-deoxy-D-manno-2-octulosonic acid transferase from Moraxella catarrhalis in lipooligosaccharide biosynthesis and virulence. Infect Immun 73: 4222-4230.
103. Maciver I, Unhanand M, McCracken GH Jr, Hansen EJ, (1993) Effect of immunization of pulmonary clearance of Moraxella catarrhalis in an animal model. J Infect Dis 168: 469-472.
104. Unhanand M, Maciver I, Ramilo O, Arencibia-Mireles O, Argyle JC, et al. (1992) Pulmonary clearance of Moraxella catarrhalis in an animal model. J Infect Dis 165: 644-650.
105. Kyd JM, Cripps AW, Murphy TF, (1998) Outer-membrane antigen expression by Moraxella (Branhamella) catarrhalis influences pulmonary clearance. J Med Microbiol 47: 159-168.
106. Murphy TF, Kyd JM, John A, Kirkham C, Cripps AW, (1998) Enhancement of pulmonary clearance of Moraxella (Branhamella) catarrhalis following immunization with outer membrane protein CD in a mouse model. J Infect Dis 178: 1667-1675.
107. Armbruster CE, Hong W, Pang B, Weimer KE, Juneau RA, et al. (2010) Indirect Pathogenicity of Haemophilus influenzae and Moraxella catarrhalis in Polymicrobial Otitis Media Occurs via Interspecies Quorum Signaling. MBio 1.
108. Brockson ME, Novotny LA, Jurcisek JA, McGillivary G, Bowers MR, et al. (2012) Respiratory syncytial virus promotes Moraxella catarrhalis-induced ascending experimental otitis media. PLoS One 7: e40088.
109. Bakaletz LO, (2009) Chinchilla as a robust, reproducible and polymicrobial model of otitis media and its prevention. Expert Rev Vaccines 8: 1063-1082.
110. Forsgren A, Riesbeck K, Janson H, (2008) Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis 46: 726-731.
111. Giebink GS, (1999) Otitis media: the chinchilla model. Microb Drug Resist 5: 57-72.
112. Giebink GS, (1997) Vaccination against middle-ear bacterial and viral pathogens. Ann N Y Acad Sci 830: 330-352.
113. Bakaletz LO, Daniels RL, Lim DJ, (1993) Modeling adenovirus type 1-induced otitis media in the chinchilla: effect on ciliary activity and fluid transport function of eustachian tube mucosal epithelium. J Infect Dis 168: 865-872.
114. Suzuki K, Bakaletz LO, (1994) Synergistic effect of adenovirus type 1 and nontypeable Haemophilus influenzae in a chinchilla model of experimental otitis media. Infect Immun 62: 1710-1718.
115. Bakaletz LO, (1995) Viral potentiation of bacterial superinfection of the respiratory tract. Trends Microbiol 3: 110-114.
116. Miyamoto N, Bakaletz LO, (1997) Kinetics of the ascension of NTHi from the nasopharynx to the middle ear coincident with adenovirus-induced compromise in the chinchilla. Microb Pathog 23: 119-126.
117. Kennedy BJ, Novotny LA, Jurcisek JA, Lobet Y, Bakaletz LO, (2000) Passive transfer of antiserum specific for immunogens derived from a nontypeable Haemophilus influenzae adhesin and lipoprotein D prevents otitis media after heterologous challenge. Infect Immun 68: 2756-2765.
118. Bakaletz LO, Kennedy BJ, Novotny LA, Duquesne G, Cohen J, et al. (1999) Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Infect Immun 67: 2746-2762.
119. Novotny LA, Jurcisek JA, Pichichero ME, Bakaletz LO, (2000) Epitope mapping of the outer membrane protein P5-homologous fimbrin adhesin of nontypeable Haemophilus influenzae. Infect Immun 68: 2119-2128.
120. McGillivary G, Bakaletz LO, (2010) The multifunctional host defense peptide SPLUNC1 is critical for homeostasis of the mammalian upper airway. PLoS One 5: e13224.
121. McGillivary G, Mason KM, Jurcisek JA, Peeples ME, Bakaletz LO, (2009) Respiratory syncytial virus-induced dysregulation of expression of a mucosal beta-defensin augments colonization of the upper airway by non-typeable Haemophilus influenzae. Cell Microbiol 11: 1399-1408.
122. McGillivary G, Ray WC, Bevins CL, Munson RS Jr, Bakaletz LO, (2007) A member of the cathelicidin family of antimicrobial peptides is produced in the upper airway of the chinchilla and its mRNA expression is altered by common viral and bacterial co-pathogens of otitis media. Mol Immunol44: 2446-2458.
123. Harris RH, Wilk D, Bevins CL, Munson RS Jr, Bakaletz LO, (2004) Identification and characterization of a mucosal antimicrobial peptide expressed by the chinchilla (Chinchilla lanigera) airway. J Biol Chem 279: 20250-20256.
124. Kerschner JE, Khampang P, Samuels T, (2010) Extending the chinchilla middle ear epithelial model for mucin gene investigation. Int J Pediatr Otorhinolaryngol 74: 980-985.
125. Kerschner JE, Erdos G, Hu FZ, Burrows A, Cioffi J, et al. (2010) Partial characterization of normal and Haemophilus influenzae-infected mucosal complementary DNA libraries in chinchilla middle ear mucosa. Ann Otol Rhinol Laryngol 119: 270-278.
126. Kerschner JE, Horsey E, Ahmed A, Erbe C, Khampang P, et al. (2009) Gene expression differences in infected and noninfected middle ear complementary DNA libraries. Arch Otolaryngol Head Neck Surg 135: 33-39.
127. Meier PS, Troller R, Heiniger N, Hays JP, van Belkum A, et al. (2006) Unveiling electrotransformation of Moraxella catarrhalis as a process of natural transformation. FEMS Microbiol Lett 262: 72-76.
128. Brooks MJ, Sedillo JL, Wagner N, Wang W, Attia AS, et al. (2008) Moraxella catarrhalis binding to host cellular receptors is mediated by sequence-specific determinants not conserved among all UspA1 protein variants. Infect Immun 76: 5322-5329.
129. Hill DJ, Virji M, (2003) A novel cell-binding mechanism of Moraxella catarrhalis ubiquitous surface protein UspA: specific targeting of the N-domain of carcinoembryonic antigen-related cell adhesion molecules by UspA1. Mol Microbiol 48: 117-129.
130. Hill DJ, Whittles C, Virji M, (2012) A novel group of Moraxella catarrhalis UspA proteins mediates cellular adhesion via CEACAMs and vitronectin. PLoS One 7: e45452.
131. Bookwalter JE, Jurcisek JA, Gray-Owen SD, Fernandez S, McGillivary G, et al. (2008) A carcinoembryonic antigen-related cell adhesion molecule 1 homologue plays a pivotal role in nontypeable Haemophilus influenzae colonization of the chinchilla nasopharynx via the outer membrane protein P5-homologous adhesin. Infect Immun 76: 48-55.
132. Holm MM, Vanlerberg SL, Sledjeski DD, Lafontaine ER, (2003) The Hag protein of Moraxella catarrhalis strain O35E is associated with adherence to human lung and middle ear cells. Infect Immun 71: 4977-4984.
133. Aebi C, Lafontaine ER, Cope LD, Latimer JL, Lumbley SL, et al. (1998) Phenotypic effect of isogenic uspA1 and uspA2 mutations on Moraxella catarrhalis 035E. Infect Immun 66: 3113-3119.